ClinVar

Description

A variant of uncertain significance has been identified in the FBN1 gene. The N1489S variant has not been published as a pathogenic variant or been reported as a benign variant to our knowledge. This variant was not observed in the Exome Aggregation Consortium or in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. Although the N1489S variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties, it occurs at a position that is conserved in mammals. Furthermore, in silico analysis predicts this variant is probably damaging to the protein structure/function. Nevertheless, although the N1489S variant is located within a calcium-binding EGF-like domain of the FBN1 gene, it does not affect a Cysteine residue. Cysteine substitutions in the calcium-binding EGF-like domains represent the majority of pathogenic missense changes associated with Marfan syndrome (Collod-Beroud et al., 2003). It should be noted that another missense substitution at the same residue (N1489K) has been reported in the Human Gene Mutation Database in association with Marfan syndrome (Stenson et al., 2014); however, it also does not affect a Cysteine residue. Additionally, although several missense substitutions in nearby residues (C1485G, C1485R, C1485Y, D1487A, C1491F, C1491Y) have been reported in association with Marfan syndrome (Stenson et al., 2014), the majority of them do affect a Cysteine residue.Therefore, based on the currently available information, it is unclear whether this variant is pathogenic or benign. This result cannot be interpreted for diagnosis or used for family member screening at this time.